{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:05:49Z","timestamp":1794535549999,"version":"4.9.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T00:00:00Z","timestamp":1586822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T00:00:00Z","timestamp":1586822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81874138"],"award-info":[{"award-number":["81874138"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81728014"],"award-info":[{"award-number":["81728014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-15-1-0117"],"award-info":[{"award-number":["W81XWH-15-1-0117"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA121974"],"award-info":[{"award-number":["P50CA121974"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA237586"],"award-info":[{"award-number":["R01CA237586"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["The Sokoloff Family-MRA Team Science Award"],"award-info":[{"award-number":["The Sokoloff Family-MRA Team Science Award"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Small molecule inhibitor of the bromodomain and extraterminal domain (BET) family proteins is a promising option for cancer treatment. However, current BET inhibitors are limited by their potency or oral bioavailability. Here we report the discovery and characterization of NHWD-870, a BET inhibitor that is more potent than three major clinical stage BET inhibitors BMS-986158, OTX-015, and GSK-525762. NHWD-870 causes tumor shrinkage or significantly suppresses tumor growth in nine xenograft or syngeneic models. In addition to its ability to downregulate c-MYC and directly inhibit tumor cell proliferation, NHWD-870 blocks the proliferation of tumor associated macrophages (TAMs) through multiple mechanisms, partly by reducing the expression and secretion of macrophage colony-stimulating factor CSF1 by tumor cells. NHWD-870 inhibits CSF1 expression through suppressing BRD4 and its target HIF1\u03b1. Taken together, these results reveal a mechanism by which BRD4 inhibition suppresses tumor growth, and support further development of NHWD-870 to treat solid tumors.<\/jats:p>","DOI":"10.1038\/s41467-020-15290-0","type":"journal-article","created":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T06:02:56Z","timestamp":1586844176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":154,"title":["Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction"],"prefix":"10.1038","volume":"11","author":[{"given":"Mingzhu","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley L.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyao","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4021-8093","authenticated-orcid":false,"given":"Rui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaohong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2354-5321","authenticated-orcid":false,"given":"Yongguang","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-636X","authenticated-orcid":false,"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4077-453X","authenticated-orcid":false,"given":"Qin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,14]]},"reference":[{"key":"15290_CR1","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature12751","volume":"502","author":"K Helin","year":"2013","unstructured":"Helin, K. & Dhanak, D. Chromatin proteins and modifications as drug targets. Nature 502, 480\u2013488 (2013).","journal-title":"Nature"},{"key":"15290_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nm.2305","volume":"17","author":"M Rodriguez-Paredes","year":"2011","unstructured":"Rodriguez-Paredes, M. & Esteller, M. Cancer epigenetics reaches mainstream oncology. Nat. Med 17, 330\u2013339 (2011).","journal-title":"Nat. Med"},{"key":"15290_CR3","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1089\/dna.2012.1654","volume":"31","author":"LP Blair","year":"2012","unstructured":"Blair, L. P. & Yan, Q. Epigenetic mechanisms in commonly occurring cancers. DNA Cell Biol. 31, S49\u2013S61 (2012).","journal-title":"DNA Cell Biol."},{"key":"15290_CR4","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2014.05.016","volume":"54","author":"J Shi","year":"2014","unstructured":"Shi, J. & Vakoc, C. R. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 54, 728\u2013736 (2014).","journal-title":"Mol. Cell"},{"key":"15290_CR5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.bbagrm.2014.03.011","volume":"1839","author":"R Sanchez","year":"2014","unstructured":"Sanchez, R., Meslamani, J. & Zhou, M. M. The bromodomain: from epigenome reader to druggable target. Biochim Biophys. Acta 1839, 676\u2013685 (2014).","journal-title":"Biochim Biophys. Acta"},{"key":"15290_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ddtec.2016.05.003","volume":"19","author":"CM Chiang","year":"2016","unstructured":"Chiang, C. M. Phospho-BRD4: transcription plasticity and drug targeting. Drug Disco. Today Technol. 19, 17\u201322 (2016).","journal-title":"Drug Disco. Today Technol."},{"key":"15290_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molcel.2005.06.029","volume":"19","author":"Z Yang","year":"2005","unstructured":"Yang, Z. et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 19, 535\u2013545 (2005).","journal-title":"Mol. Cell"},{"key":"15290_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.molcel.2005.06.027","volume":"19","author":"MK Jang","year":"2005","unstructured":"Jang, M. K. et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 19, 523\u2013534 (2005).","journal-title":"Mol. Cell"},{"key":"15290_CR9","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature10334","volume":"478","author":"J Zuber","year":"2011","unstructured":"Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524\u2013528 (2011).","journal-title":"Nature"},{"key":"15290_CR10","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904\u2013917 (2011).","journal-title":"Cell"},{"key":"15290_CR11","doi-asserted-by":"publisher","first-page":"16669","DOI":"10.1073\/pnas.1108190108","volume":"108","author":"JA Mertz","year":"2011","unstructured":"Mertz, J. A. et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. USA 108, 16669\u201316674 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"15290_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Loven","year":"2013","unstructured":"Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320\u2013334 (2013).","journal-title":"Cell"},{"key":"15290_CR13","doi-asserted-by":"publisher","first-page":"6380","DOI":"10.1073\/pnas.0710331105","volume":"105","author":"NP Crawford","year":"2008","unstructured":"Crawford, N. P. et al. Bromodomain 4 activation predicts breast cancer survival. Proc. Natl Acad. Sci. USA 105, 6380\u20136385 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"15290_CR14","first-page":"304","volume":"63","author":"CA French","year":"2003","unstructured":"French, C. A. et al. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res 63, 304\u2013307 (2003).","journal-title":"Cancer Res"},{"key":"15290_CR15","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067\u20131073 (2010).","journal-title":"Nature"},{"key":"15290_CR16","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.1021\/acs.jmedchem.5b00613","volume":"58","author":"X Ran","year":"2015","unstructured":"Ran, X. et al. Structure-based design of gamma-carboline analogues as potent and specific BET bromodomain inhibitors. J. Med Chem. 58, 4927\u20134939 (2015).","journal-title":"J. Med Chem."},{"key":"15290_CR17","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.1021\/acs.jmedchem.6b01761","volume":"60","author":"Z Liu","year":"2017","unstructured":"Liu, Z. et al. Drug discovery targeting bromodomain-containing protein 4. J. Med Chem. 60, 4533\u20134558 (2017).","journal-title":"J. Med Chem."},{"key":"15290_CR18","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-12-3292","volume":"73","author":"S Picaud","year":"2013","unstructured":"Picaud, S. et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains. Cancer Res 73, 3336\u20133346 (2013).","journal-title":"Cancer Res"},{"key":"15290_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","volume":"24","author":"B Chapuy","year":"2013","unstructured":"Chapuy, B. et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24, 777\u2013790 (2013).","journal-title":"Cancer Cell"},{"key":"15290_CR20","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","volume":"28","author":"DB Doroshow","year":"2017","unstructured":"Doroshow, D. B., Eder, J. P. & LoRusso, P. M. BET inhibitors: a novel epigenetic approach. Ann. Oncol. 28, 1776\u20131787 (2017).","journal-title":"Ann. Oncol."},{"key":"15290_CR21","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/nchembio.2209","volume":"12","author":"M Tanaka","year":"2016","unstructured":"Tanaka, M. et al. Design and characterization of bivalent BET inhibitors. Nat. Chem. Biol. 12, 1089\u20131096 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"15290_CR22","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.1521738113","volume":"113","author":"K Raina","year":"2016","unstructured":"Raina, K. et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 113, 7124\u20137129 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"15290_CR23","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter, G. E. et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376\u20131381 (2015).","journal-title":"Science"},{"key":"15290_CR24","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98, 8554\u20138559 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"15290_CR25","doi-asserted-by":"publisher","first-page":"103713","DOI":"10.1016\/j.cellimm.2017.10.013","volume":"343","author":"J Schupp","year":"2019","unstructured":"Schupp, J. et al. Targeting myeloid cells in the tumor sustaining microenvironment. Cell Immunol. 343, 103713 (2019).","journal-title":"Cell Immunol."},{"key":"15290_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.cell.2006.01.007","volume":"124","author":"J Condeelis","year":"2006","unstructured":"Condeelis, J. & Pollard, J. W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124, 263\u2013266 (2006).","journal-title":"Cell"},{"key":"15290_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39\u201351 (2010).","journal-title":"Cell"},{"key":"15290_CR28","doi-asserted-by":"crossref","unstructured":"Yin, M., et al. ASK1-dependent endothelial cell activation is critical in ovarian cancer growth and metastasis. JCI Insight 2, 91828 (2017).","DOI":"10.1172\/jci.insight.91828"},{"key":"15290_CR29","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1172\/JCI87252","volume":"126","author":"M Yin","year":"2016","unstructured":"Yin, M. et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J. Clin. Invest. 126, 4157\u20134173 (2016).","journal-title":"J. Clin. Invest."},{"key":"15290_CR30","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccr.2013.02.013","volume":"23","author":"M De Palma","year":"2013","unstructured":"De Palma, M. & Lewis, C. E. Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23, 277\u2013286 (2013).","journal-title":"Cancer Cell"},{"key":"15290_CR31","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl, C. et al. Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N. Engl. J. Med 362, 875\u2013885 (2010).","journal-title":"N. Engl. J. Med"},{"key":"15290_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ajpath.2013.09.017","volume":"184","author":"SY Ko","year":"2014","unstructured":"Ko, S. Y., Ladanyi, A., Lengyel, E. & Naora, H. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am. J. Pathol. 184, 271\u2013281 (2014).","journal-title":"Am. J. Pathol."},{"key":"15290_CR33","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.4049\/jimmunol.176.8.5023","volume":"176","author":"T Hagemann","year":"2006","unstructured":"Hagemann, T. et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J. Immunol. 176, 5023\u20135032 (2006).","journal-title":"J. Immunol."},{"key":"15290_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.21873\/anticanres.11304","volume":"37","author":"T Miura","year":"2017","unstructured":"Miura, T. et al. Prognostic impact of CD163+ macrophages in tumor stroma and CD8+ T-cells in cancer cell nests in invasive extrahepatic bile duct cancer. Anticancer Res 37, 183\u2013190 (2017).","journal-title":"Anticancer Res"},{"key":"15290_CR35","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck, S. M. et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med 19, 1264\u20131272 (2013).","journal-title":"Nat. Med"},{"key":"15290_CR36","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.molcel.2012.12.006","volume":"49","author":"SY Wu","year":"2013","unstructured":"Wu, S. Y., Lee, A. Y., Lai, H. T., Zhang, H. & Chiang, C. M. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol. Cell 49, 843\u2013857 (2013).","journal-title":"Mol. Cell"},{"key":"15290_CR37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16508","volume":"529","author":"S Shu","year":"2016","unstructured":"Shu, S. et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature 529, 413\u2013417 (2016).","journal-title":"Nature"},{"key":"15290_CR38","first-page":"1834","volume":"5","author":"PP Sharp","year":"2014","unstructured":"Sharp, P. P., Carnier, J. M., Huang, D. C. S. & Burns, C. J. Evaluation of functional groups as acetyl-lysine mimetics for BET bromodomain inhibition. ChemMedChem 5, 1834\u20131842 (2014).","journal-title":"ChemMedChem"},{"key":"15290_CR39","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1158\/1535-7163.MCT-16-0141","volume":"15","author":"GW Rhyasen","year":"2016","unstructured":"Rhyasen, G. W. et al. AZD5153: a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies. Mol. Cancer Ther. 15, 2563\u20132574 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"15290_CR40","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1158\/0008-5472.CAN-16-1793","volume":"77","author":"MH Bui","year":"2017","unstructured":"Bui, M. H. et al. Preclinical characterization of BET family bromodomain inhibitor ABBV-075 suggests combination therapeutic strategies. Cancer Res 77, 2976\u20132989 (2017).","journal-title":"Cancer Res"},{"key":"15290_CR41","doi-asserted-by":"crossref","unstructured":"Chaturvedi P., Gilkes D. M., Takano N., & Semenza G. L. Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. Proc. Natl Acad. Sci. USA 111, E2120\u2013E2129 (2014).","DOI":"10.1073\/pnas.1406655111"},{"key":"15290_CR42","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","volume":"30","author":"WG Kaelin Jr.","year":"2008","unstructured":"Kaelin, W. G. Jr. & Ratcliffe, P. J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30, 393\u2013402 (2008).","journal-title":"Mol. Cell"},{"key":"15290_CR43","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1128\/MCB.01514-06","volume":"27","author":"Q Yan","year":"2007","unstructured":"Yan, Q., Bartz, S., Mao, M., Li, L. & Kaelin, W. G. Jr. The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol. Cell Biol. 27, 2092\u20132102 (2007).","journal-title":"Mol. Cell Biol."},{"key":"15290_CR44","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1172\/JCI95089","volume":"128","author":"Y Chen","year":"2018","unstructured":"Chen, Y. et al. ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis. J. Clin. Invest 128, 1937\u20131955 (2018).","journal-title":"J. Clin. Invest"},{"key":"15290_CR45","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-018-0158-8","volume":"24","author":"F Zanconato","year":"2018","unstructured":"Zanconato, F. et al. Transcriptional addiction in cancer cells is mediated by YAP\/TAZ through BRD4. Nat. Med 24, 1599\u20131610 (2018).","journal-title":"Nat. Med"},{"key":"15290_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1158\/2159-8290.CD-17-0461","volume":"8","author":"M Rusan","year":"2018","unstructured":"Rusan, M. et al. Suppression of adaptive responses to targeted cancer therapy by transcriptional repression. Cancer Discov. 8, 59\u201373 (2018).","journal-title":"Cancer Discov."},{"key":"15290_CR47","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature14898","volume":"525","author":"P Rathert","year":"2015","unstructured":"Rathert, P. et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 525, 543\u2013547 (2015).","journal-title":"Nature"},{"key":"15290_CR48","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature14888","volume":"525","author":"CY Fong","year":"2015","unstructured":"Fong, C. Y. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525, 538\u2013542 (2015).","journal-title":"Nature"},{"key":"15290_CR49","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/nm.4379","volume":"23","author":"P Zhang","year":"2017","unstructured":"Zhang, P. et al. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat. Med 23, 1055\u20131062 (2017).","journal-title":"Nat. Med"},{"key":"15290_CR50","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nm.4372","volume":"23","author":"H Janouskova","year":"2017","unstructured":"Janouskova, H. et al. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat. Med 23, 1046\u20131054 (2017).","journal-title":"Nat. Med"},{"key":"15290_CR51","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/nm.4378","volume":"23","author":"X Dai","year":"2017","unstructured":"Dai, X. et al. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat. Med 23, 1063\u20131071 (2017).","journal-title":"Nat. Med"},{"key":"15290_CR52","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","volume":"10","author":"L Yang","year":"2017","unstructured":"Yang, L. & Zhang, Y. Tumor-associated macrophages: from basic research to clinical application. J. Hematol. Oncol. 10, 58 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"15290_CR53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49\u201361 (2014).","journal-title":"Immunity"},{"key":"15290_CR54","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1158\/0008-5472.CAN-06-4375","volume":"67","author":"TM Robinson-Smith","year":"2007","unstructured":"Robinson-Smith, T. M. et al. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res 67, 5708\u20135716 (2007).","journal-title":"Cancer Res"},{"key":"15290_CR55","doi-asserted-by":"publisher","first-page":"5278","DOI":"10.1158\/0008-5472.CAN-04-1853","volume":"65","author":"S Goswami","year":"2005","unstructured":"Goswami, S. et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1\/epidermal growth factor paracrine loop. Cancer Res 65, 5278\u20135283 (2005).","journal-title":"Cancer Res"},{"key":"15290_CR56","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/onc.2016.184","volume":"36","author":"LL da Motta","year":"2017","unstructured":"da Motta, L. L. et al. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. Oncogene 36, 122\u2013132 (2017).","journal-title":"Oncogene"},{"key":"15290_CR57","unstructured":"Zhang X., Goncalves R. & Mosser D. M. The isolation and characterization of murine macrophages. Curr. Protoc. Immunol. Chapter 14, Unit 14 11 (2008)."},{"key":"15290_CR58","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675 (2012).","journal-title":"Nat. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15290-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15290-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15290-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T15:31:17Z","timestamp":1670254277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-15290-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,14]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["15290"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-15290-0","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737748156.793573894","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,14]]},"assertion":[{"value":"6 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.W. is the founder of Ningbo Wenda Pharma. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1833"}}